Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 291 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 291 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares in the company, valued at $10,514,550.48. This represents a 0.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Up 7.5%

Twist Bioscience stock opened at $91.35 on Thursday. The stock has a market capitalization of $5.69 billion, a PE ratio of -68.68 and a beta of 2.23. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $93.80. The business has a 50 day simple moving average of $65.38 and a 200-day simple moving average of $50.64. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter last year, the business earned ($0.66) EPS. The company’s quarterly revenue was up 19.3% on a year-over-year basis. On average, analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the business. ARK Investment Management LLC raised its position in shares of Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after buying an additional 832,687 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after buying an additional 1,349,867 shares in the last quarter. William Blair Investment Management LLC boosted its position in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. boosted its position in Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Finally, State Street Corp grew its stake in Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after acquiring an additional 538,755 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. TD Cowen lifted their target price on shares of Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, June 15th. UBS Group set a $89.00 price target on shares of Twist Bioscience in a research report on Monday, June 15th. Robert W. Baird raised their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Leerink Partners set a $80.00 price objective on Twist Bioscience in a research note on Friday, May 22nd. Finally, Guggenheim increased their target price on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $74.60.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.